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 Congenital stationary night blindness (CSNB) is a
nonprogressive retinal disorder characterized by a negative-
type ERG in which the amplitude of the b-wave is smaller
than that of the a-wave [1] even though the fundus of CSNB
patients is essentially normal. Nystagmus, strabismus, myo-
pia, and hyperopia sometimes accompany the other symptoms
[2]. The disease is transmitted in an autosomal recessive, au-
tosomal dominant or X-linked mode of inheritance. Several
groups have shown genetic heterogeneity of the X-linked form
of congenital stationary night blindness (XLCSNB) by iden-
tification of two different loci on chromosome X (CSNB1 and
CSNB2) [3]. In addition, based on the electroretinogram
(ERG), XLCSNB can be divided clinically into two subtypes
[4] namely the incomplete type (OMIM 300071) and the com-
plete type (OMIM 310500). While in patients with the incom-
plete type still some post-receptoral rod mediated function is
measurable by ERG, no activity is retained in the complete
subtype. However, cone function is more impaired in the in-
complete type, as revealed by scotopic 30 hertz flicker re-
sponses after dark adaptation tests [5-7].
CACNA1F, a gene that maps to Xp11.23, encodes the α-
1F subunit of an L-type calcium channel and was identified as
the gene mutated in patients with the incomplete form of
XLCSNB [8,9]. CACNA1F consists of 48 exons and codes
for a protein with 1966 amino acids. Originally it was believed
that its expression is restricted to the retina, but recently it
was found that it is widely distributed outside the retina, sug-
gesting a broader role in human physiology [8-10].
By positional cloning, we and others have isolated a gene
in Xp11.4, NYX (nyctalopin), that is mutated in CSNB1 pa-
tients [11,12]. It consists of three exons and encodes a 481
amino acid polypeptide of the leucine rich repeat family (LRR).
Recently, we isolated the mouse ortholog of NYX [13] and
showed that the human and mouse nyctalopin are extracellu-
lar, membrane bound proteins [14].
Although previous studies have linked mutations in
CACNA1F and NYX to the incomplete and complete forms of
XLCSNB, respectively, recent genotype-phenotype compari-
sons showed no correlation [15]. Noticeably, the frequency of
the types of mutations is different in both genes. To our knowl-
edge, 73 CACNA1F mutations have been identified in patients
with XLCSNB; 51% are nonsense mutations, 32% are mis-
sense mutations, 8% are frameshift mutations, 8% are in-frame
deletions or insertions, and 1% represent splice site mutations
[8,9,15-20]. Of the 53 NYX mutations reported so far, 51% of
them account for missense mutations, 32% for in-frame inser-
tions or deletions, 7% for frameshift mutations, 4% for large
deletions, only 4% for nonsense mutations, and 2% for splice
site mutations [11,12,15,16].
In this study, we screened eight unrelated Dutch XLCSNB
patients for mutations in the CACNA1F and/or NYX genes.
METHODS
Patients:  Eight unrelated patients were diagnosed with
XLCSNB at the University Medical Center of Nijmegen by
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different tests, notably analysis of the pedigree, electroretin-
ography (ERG), and electro-oculography (EOG).
For ERG tests, a scleral contact lens equipped with mea-
suring electrodes was inserted. A reference electrode was
placed on the forehead and the patient was earthed by means
of two earclip electrodes. Two 40 W incandescent lamps were
applied to furnish a Ganzfeld adaptation and a Xenon flash
was used for stimulation (flash luminescence was 6.85 cd/m2
photopic and 0.8 cd/m2 scotopic, respectively). Measurements
were recorded during photopic and scotopic (after a 12 min
dark adaptation) circumstances. Recorded electric potentials
were plotted against flash intensity and the voltage of the re-
sponse was determined for both eyes as the average between
the measurement at 0.2 and 0.4 joules for photopic circum-
stances and the response after 12 min dark adaptation for the
scotopic measurement. The lower limit of normality with this
technique was 10 µV for the photopic b-wave and 150 µV for
the scotopic b-wave with a white stimulus [21]. EOG was per-
formed by placing electrodes on the skin of the lateral and
medial canthi. After pre-adaptation at 100 Lux, the sphere was
darkened and the EOG was recorded every 2 min during 12
min. This was followed by a recording every min at 2500 Lux
during another 15 min. Subsequently, the ratio between the
dark trough and the light peak was determined (Arden ratio).
Details of these techniques were described previously [21].
Mutation screening:  Genomic DNA was isolated from
EBV transformed lymphoblastoid cells by standard techniques.
CACNA1F exons were amplified with intronic primers [19].
PCR amplified fragments from 48 exons of the CACNA1F
gene were first examined either with denaturing high perfor-
mance liquid chromatography (DHPLC) or single stranded
conformation polymorphism (SSCP) analysis [22,23]. Probes
resulting in different elution profiles or band shifts were se-
quenced on an automated DNA sequencer (ABI PRISM 3100,
Applied Biosystems, Rotkreuz, Switzerland).
NYX exons were amplified with intronic primers as fol-
lows: exon 1 and exon 2 within one fragment with HotStarTaq
DNA Polymerase and Q-solution (Qiagen, Hombrechtikon,
Switzerland), 1.5 mM MgCl2 at 56 °C annealing temperature
with a forward and a reverse primer (5'-CCG GGG ATA AAG
CCG ATT GG-3' and 5'-GAA GCT CTG TGG CTT CCA CC-
3'). Additional nested primers for the sequencing of exon 1
and exon 2 of NYX were: 5'-CTT AGC CC AAC ACC AGG
GTC-3' and for the sequencing of exon 3: 5'-CCT CAC CAC
GTC CAG TCC-3', and 5'-GTC TCC ATC GAC CTG GAC
C-3'.
Exon 3 was amplified as three fragments (A, B, C) with
different forward and reverse primer combinations. Fragment
A (primers 5'-TTC TCC TCC TTC CCG ACT C-3' and 5'-
CGG CAG GCT GCT AGG TCT-3') was amplified using with
HotStarTaq DNA Polymerase and Q-solution (Qiagen), 2.5
mM MgCl2 at 58 °C annealing temperature. Fragments B
(primers 5'-GAC CTG CGC TAC CTG CAC-3' and 5'-CGG
AGC CCT CCA GT-3') and C (primers 5'-GCT CAA CGA
CAA CCT GCT G-3' and 5'-ACA AAC ACA CTC AAG CCC
AG-3') of exon 3 were both amplified with HotStarTaq Poly-
merase and Q-solution (Qiagen), 1.5 mM MgCl2 at 58 °C and
60 °C annealing temperature.
RESULTS & DISCUSSION
 Eight patients were diagnosed with CSNB Schubert-
Bornschein type by ERG and EOG (Table 1). One of them
(2490) showed a clear X-linked mode of inheritance. When
the patients were originally examined, they were not classi-
fied as complete or incomplete forms of XLCSNB. A geno-
type-phenotype correlation in British XLCSNB families re-
vealed that a discrimination between the two forms can be
made by analyzing the scotopic oscillatory potentials, the 30
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TABLE 1. CLINICAL DATA OF THE DESCRIBED PATIENTS
                                                                     Photopic        Electro-
                                Visual     Scotopic ERG RE/LE       ERG RE/LE       oculography
                       Age      acuity     ------------------    ----------------     (lp/dt)
                        at    ----------    a-wave     b-wave    a-wave    b-wave   -----------      Dark
Patient   Diagnosis    exam   RE     LE      [µV]       [µV]      [µV]      [µV]     RE     LE    adaptation   Nystagmus
-------   ----------   ----   ---   ----   --------   --------   -------   ------   ----   ----   ----------   ---------
 2417     CSNB,         27    0.8   0.3     30/ 25     60/70       0/100   60/70    1.75   1.94    -           Yes
          ablation
          LE
 2436     CSNB          34    0.3   0.3     90/ 80     20/25      60/ 50   35/40     -      -      Affected    Yes
 2445     CSNB,         19    0.4   0.4     50/ 70     50/75      35/ 55   60/70     -      -      Affected    Yes
          strabismus
 2446     CSNB          11    0.2   0.2    130/ 70     50/60      75/ 50   30/20     -      -      Normal      Yes
 2454     CSNB          11    0.2   0.2     15/ 15     50/60      45/ 45   50/50    2.24   2.2     Affected    Yes (L>R)
 2477     CSNB,         36    0.3   0.3    110/100      5/20     100/ 85   10/10    1.26   1.38    Affected    Yes
          tilted
          disc
 2490     CSNB          66                  20/ 20     90/90      50/ 50   30/40     -      -      -           Unknown
 2496     CSNB,          8    0.4   0.4     60/NM      40/NM      75/ 65   55/55     -      -      -           Yes
          strabismus
The clinical data of eight Dutch patients shows typical findings for patients with XLCSNB. Right eye (RE), left eye (LE), electroretinogram
(ERG), light peak/dark trough (lp/dt), and not measured (NM) are abbreviated in the table. The retina of the left eye was ablated in patient
2417.
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Hz flicker ERG, and the OFF response [15]. However, these
data were not available for the patients described here. In fu-
ture studies these ERG measurements always should be per-
formed, providing a genotype-phenotype correlation. This
would allow preselecting patients associated with one or the
other form, which would make the mutation analysis in both
genes less time and cost consuming.
 Mutation analysis in CACNA1F in XLCSNB patients re-
vealed three novel and two known sequence variants in five
independent families (Table 2). None of the mutations were
detected in 100 control chromosomes from European individu-
als. The novel C to T nonsense mutation at position 2038 in
exon 15 is predicted to lead to a version of the protein that is
shortened by 1286 amino acids. The C to T nonsense muta-
tion at position 2650 in exon 21 likewise causes a protein trun-
cation and was previously identified in another family [11].
The two novel CACNA1F mutations G to T at position 3761
and C to A at position 3853 lead to the amino acid substitu-
tions S1254I and R1285S, respectively. The known missense
mutation G to A at position 5756 has been previously identi-
fied in 21 control alleles in the Japanese population [17]. Thus,
we conclude that this latter sequence variant is most likely
non-causative and that the polymorphism occurs more fre-
quently in the Japanese population than in Europeans. This is
an assumption that must be verified in the future. However,
computational analysis by means of exonic splicing enhancer
prediction software (ESE version 1.1) provided evidence that
the G to A mutation at position 5756 is located in an ESE site
of exon 48 and thus may affect normal splicing (data not
shown). Further experimental studies are necessary to con-
firm this prediction.
Protein sequence alignments of CACNA1F have shown
homology to the L-type calcium channel α-1 subunit. The α-
1 subunits function as the pore and voltage sensor in ion se-
lective L-type calcium channels [24-26]. The novel stop mu-
tation found in exon 15 is situated in the extracellular loop in
the second domain (II), thereby deleting about two thirds of
the protein, including part of domain II, the entirety of do-
mains III and IV, the EF-hand motif, and the cytoplasmic C-
terminus. The stop mutation in exon 21 occurs in the extracel-
lular loop of the third domain (III), thereby deleting part of
domain III, the entirety of domain IV, the EF-hand motif, and
the cytoplasmic C-terminus. The novel missense mutations
detected in exons 31 and 33 affect the potential transmem-
brane segments S3 and S4 of repeat IV of the CACNA1F pro-
tein. Although the consequences of the mutations on channel
function have not been investigated, it appears most likely
that the incomplete type of CSNB is associated with loss of
function mutations. Presumably they decrease the calcium
influx and tonic glutamate release in darkness with consequent
relative depolarization of bipolar cells [27], leading to the typi-
cal reduced ERG b-wave found in patients with the incom-
plete type of CSNB.
Mutation screening in NYX revealed two novel missense
mutations in exon 3, in two different families, that were not
detected in 100 control alleles (Table 3). Nyctalopin was shown
to be an LRR cell surface protein attached extracellularly to
the membrane [14]. The P57T exchange in patient 2436 oc-
curs in the N-terminal cysteine LRR and the A64E amino acid
substitution in patient 2454 in the first typical LRR in patient
2454. Both residues are conserved in human and mouse
nyctalopin [13]. Previous studies have shown that mutations
in the RP2 gene can disrupt the correct subcellular localiza-
tion, presumably leading to the phenotype diagnosed in pa-
tients with retinitis pigmentosa (RP2) [28]. However, differ-
ent constructs containing disease associated mutations found
in NYX have not shown any effect on the cellular localization
in comparison to wild type constructs [14]. Thus, the function
of this protein remains to be elucidated. Many LRR proteins
have been found to be involved in protein-protein interactions
[29]. Consequently, the mutated variants may disrupt these
processes leading to congenital stationary night blindness.
In this study, we detected in seven of eight unrelated CSNB
diagnosed patients sequence variants, five of which were novel.
Our results confirm previous findings that most pathogenic
sequence alterations in CACNA1F are nonsense mutations,
while missense mutations are predominant in NYX. Further-
more, one alteration was already known to be a polymorphism
in Japanese families. In one patient (2445), we could rule out
the presence of NYX and CACNA1F mutations. In this case,
other, not yet identified coding or regulatory sequences of NYX
and CACNA1F or additional genes may be mutated. Addi-
tionally, we cannot exclude that this patient has a different
mode of inheritance of CSNB.
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TABLE 2. SEQUENCE VARIANTS IN THE CACNA1F GENE
Patient   Exon   Mutation   Protein   Reference
-------   ----   --------   -------   ---------
 2446      15    2038C>T    R680X
 2477      21    2650C>T    R884X      [8,19]
 2417      31    3761G>T    S1254I
 2490      33    3853C>A    R1285S
 2496      48    5756G>A    R1919H     [17]
Three novel mutations in the CACNA1F gene. R884X has been pre-
viously found by Bech-Hansen et al. [8] in one patient and by Strom
et al. [9] in two unrelated patients. R1919H has been previously found
in one patient and described as a polymorphism in 21 of 100 control
alleles [17]. The nucleotide positions in the mutation column are based
on the start codon of the CACNA1F gene (AJ006216).
TABLE 3. SEQUENCE VARIANTS IN THE NYX GENE
Patient   Exon   Mutation   Protein
-------   ----   --------   -------
 2436      3      169C>A     P57T
 2454      3      191C>A     A64E
Two novel mutations in the NYX gene. The nucleotide positions in
the mutation column are based on the start codon in the NYX (gene
originally named CLRP; AJ278865).
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